Select Page

EVQLV

EVQLV CEO’s Article Published in ‘Life Science Leader’

EVQLV CEO’s Article Published in ‘Life Science Leader’

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

read more
Andrew Satz on the ‘Amplifying Scientific Innovation’ Podcast with Dr. Sophia Ononye-Onyia

Andrew Satz on the ‘Amplifying Scientific Innovation’ Podcast with Dr. Sophia Ononye-Onyia

EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).

read more
EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

read more